Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
GLP-1 Receptor Agonist
100%
Opioid Use Disorder
100%
A1 Receptor
78%
Glucagon-like
78%
Receptor Agonist
55%
Fentanyl
40%
Liraglutide
39%
Counseling
24%
Medications for Opioid Use Disorder
21%
Semaglutide
20%
Drug Cues
18%
Buprenorphine
18%
Brain Response
18%
Drug Response
18%
Heroin Seeking
15%
Naltrexone
13%
Residential Treatment
13%
Drug-induced Reinstatement
13%
Stress-induced Reinstatement
13%
Heroin
13%
Type 2 Diabetes Mellitus (T2DM)
13%
Opioids
13%
Methadone
13%
Heroin Self-administration
10%
Stress-induced
9%
Obesity Treatment
9%
Non-opioid
9%
Cocaine
9%
Nicotine
9%
Satiety
9%
Once-daily Regimen
9%
Phase III Clinical Trial
9%
United States
9%
Alcohol
9%
Specific Intent
8%
Cardiovascular Dysregulation
8%
Respiratory Depression
8%
Patient's Will
8%
Polysomnography
8%
Slow-wave Sleep
8%
Sleep Problems
8%
Relapse Rate
5%
Addiction
5%
Sweetwater
5%
Reward Pathway
5%
Disease Prevention
5%
Randomized Double-blind
5%
Sodium
5%
Multicenter Clinical Trial
5%
Placebo-controlled
5%
Opioid Relapse
5%
Drug Overdose Deaths
5%
Extended-release Naltrexone
5%
Placebo
5%
Randomized Placebo-controlled Trial
5%
Centers for Disease Control
5%
Short-acting
5%
Hijacking
5%
Medicine and Dentistry
Glucagon-Like Peptide-1 Agonist
60%
Opioid Abuse
60%
Diamorphine
36%
Semaglutide
22%
Naltrexone
19%
Liraglutide
18%
Placebo
17%
Buprenorphine
16%
Diseases
16%
Glucagon Like Peptide 1 Receptor
16%
Clinical Trial
16%
Self-Administration
11%
Methadone
10%
Drug Overdose
8%
Ingestion
8%
Satiety
8%
Buprenorphine Plus Naloxone
8%
Maturity Onset Diabetes of the Young
8%
Outpatient
5%
Arm
5%
Addictive Behavior
5%
Recurrence Risk
5%
Table Salt
5%
Slow-Wave Sleep
5%
Polysomnography
5%
Sleep Disorder
5%